MedTrace Logo

Ga-68 PSMA-11 PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: Digital PET/CT Versus Analog PET/CT

NCT04846894 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2021-09-29

No results posted yet for this study

Summary

Ga-68 PSMA-11 PET/CT is known as useful method for localizing recurred tumor lesions in prostate cancer patients with biochemical recurrence \[elevated serum prostate specific antigen (PSA) after radical prostatectomy\]. The recent digital PET/CT which is known to show better resolution and sensitivity than analogue PET/CT may have better performance for detecting early small recurred tumor lesions. This study is intended to compare the diagnostic performance (detection rate and positive predictive value) of Ga-68 PSMA-11 PET/CT using analogue PET/CT scanner and digital PET/CT scanner in same patients who had biochemical recurrence of prostate cancer.

Conditions

Interventions

DIAGNOSTIC_TEST

Ga-68 PSMA-11 PET/CT imaging

Sequential PET/CT imaging using analog and digital PET/CT scanners after single intravenous injection of Ga-68 PSMA-11

Sponsors & Collaborators

  • Jin-Sook Ryu

    lead OTHER

Principal Investigators

  • Jin-Sook Ryu, MD.PhD. · Asan Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-13
Primary Completion
2022-06-30
Completion
2023-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04846894 on ClinicalTrials.gov